Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: Feasibility and contrast agent dose

Radiology

Volumn 234, Issue 3, 2005, Pages 869-877

  Manka, Christoph ^a   Träber, Frank ^a   Gieseke, Juergen ^a   Schild, Hans H ^a   Kuhl, Christiane K ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; BRAIN PERFUSION; CLINICAL ARTICLE; ECHO PLANAR IMAGING; FEMALE; FIRST PASS EFFECT; GRAY MATTER; HUMAN; IMAGE QUALITY; MALE; MEAN RESIDENCE TIME; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO; THREE DIMENSIONAL IMAGING;

ADULT; AGED; BRAIN DISEASES; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; ECHO-PLANAR IMAGING; FEASIBILITY STUDIES; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 13844256798     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2343040359     Document Type: Article

References (53)

1. Flacke S, Urbach H, Folkers PJ, et al. Ultra-fast three-dimensional MR perfusion imaging of the entire brain in acute stroke assessment. J Magn Reson Imaging 2000; 11:250-259.
2. Fiehler J, von Bezold M, Kucinski T, et al. Cerebral blood flow predicts lesion growth in acute stroke patients. Stroke 2002; 33:2421-2425.
3. Liu Y, Karonen JO, Vanninen RL, et al. Cerebral hemodynamics in human acute ischemic stroke: a study with diffusion- and perfusion-weighted magnetic resonance imaging and SPECT. J Cereb Blood Flow Metab 2000; 20: 910-920.
4. Parsons MW, Yang Q, Barber PA, et al. Perfusion magnetic resonance imaging maps in hyperacute stroke: relative cerebral blood flow most accurately identifies tissue destined to infarct. Stroke 2001; 32:1581-1587.
5. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: a scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 2003; 34:1084-1104.
6. Doerfler A, Eckstein HH, Eichbaum M, et al. Perfusion-weighted magnetic resonance imaging in patients with carotid artery disease before and after carotid endarterectomy. J Vasc Surg 2001; 34:587-593.
7. Calamante F, Ganesan V, Kirkham FJ, et al. MR perfusion imaging in Moyamoya syndrome: potential implications for clinical evaluation of occlusive cerebrovascular disease. Stroke 2001; 32:2810-2816.
8. Maeda M, Yuh WT, Ueda T, et al. Severe occlusive carotid artery disease: hemodynamic assessment by MR perfusion imaging in symptomatic patients. AJNR Am J Neuroradiol 1999; 20:43-51.
9. Michel E, Liu H, Remley KB, et al. Perfusion MR neuroimaging in patients undergoing balloon test occlusion of the internal carotid artery. AJNR Am J Neuroradiol 2001; 22:1590-1596.
10. Hartmann M, Heiland S, Sartor K. Functional MRI procedures in the diagnosis of brain tumors: perfusion- and diffusion-weighted imaging. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2002; 174:955-964. [German]
11. Kassner A, Annesley DJ, Zhu XP, et al. Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000; 11:103-113.
12. Le Bihan D, Douek P, Argyropoulou M, Turner R, Patronas N, Fulham M. Diffusion and perfusion magnetic resonance imaging in brain tumors. Top Magn Reson Imaging 1993; 5:25-31.
13. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen AG. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 2002; 178:711-716.
14. Sartor K. MR imaging of the brain: tumors. Eur Radiol 1999; 9:1047-1054.
15. Alexander E III. Optimizing brain tumor resection: midfield interventional MR imaging. Neuroimaging Clin N Am 2001; 11:659-672.
16. Lee SJ, Kim JH, Kim YM, et al. Perfusion MR imaging in gliomas: comparison with histologic tumor grade. Korean J Radiol 2001; 2:1-7.
17. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993; 189:233-238.
18. Vonken EP, Van Osch MJ, Willems PW, et al. Repeated quantitative perfusion and contrast permeability measurement in the MRI examination of a CNS tumor. Eur Radiol 2000; 10:1447-1451.
19. Hartmann M, Heiland S, Harting I, et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003; 338:119-122.
20. Aichner F, Wagner M, Kremser C, Felber S. MR-imaging of non-Alzheimer's dementia. J Neural Transm Suppl 1996; 47:143-153.
21. Bozzao A, Floris R, Baviera ME, Apruzzese A, Simonetti G. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol 2001; 22:1030-1036.
22. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003; 20:1309-1319.
23. Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke 2000; 31:1904-1912.
24. Brusa L, Bassi A, Pierantozzi M, Gaudiello SF, Floris R, Stanzione P. Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease. Neurol Sci 2002; 23(suppl 2):S61-S62.
25. Maas LC, Hams GJ, Satlin A, English CD, Lewis RF, Renshaw PF. Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. J Magn Reson Imaging 1997; 7:215-219.
26. Edelman RR, Mattle HP, Atkinson DJ, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology 1990; 176:211-220.
27. Fisel CR, Ackerman JL, Buxton RB, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med 1991; 17:336-347.
28. Rosen BR, Belliveau JW, Buchbinder BR, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991; 19:285-292.
29. Erb G, Benner T, Heiland S, Reith W, Sartor K, Forsting M. Studies on contrast medium dosage in perfusion-weighted MR imaging. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997; 167:599-604. [German]
30. Keston P, Murray AD, Jackson A. Cerebral perfusion imaging using contrast-enhanced MRI. Clin Radiol 2003; 58:505-513.
31. Tombach B, Benner T, Reimer P, et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 2003; 226:880-888.
32. Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 2003; 228:523-532.
33. Flacke S, Urbach H, Block W, et al. Perfusion and molecular diffusion-weighted MR imaging of the brain: in vivo assessment of tissue alteration in cerebral ischemia. Amino Acids 2002; 23:309-316.
34. Baird AE, Lovblad KO, Dashe JF, et al. Clinical correlations of diffusion and perfusion lesion volumes in acute ischemic stroke. Cerebrovasc Dis 2000; 10:441-448.
35. Benner T, Reimer P, Erb G, et al. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study. J Magn Reson Imaging 2000; 12:371-380.
36. Essig M, Lodemann KP, LeHuu M, Schonberg SO, Hubener M, Van Kaick G. Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers. Radiologe 2002; 42:909-915. [German]
37. Trattnig S. 3 Tesla magnetic resonance tomography: clinical applications. Wien Med Wochenschr Suppl 2002; 113:22-27. [German]
38. Gati JS, Menon RS, Ugurbil K, Rutt BK. Experimental determination of the BOLD field strength dependence in vessels and tissue. Magn Reson Med 1997; 38:296-302.
39. Wang J, Alsop DC, Li L, et al. Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla. Magn Reson Med 2002; 48:242-254.
40. Kruger G, Kastrup A, Glover GH. Neuroimaging at 1.5 T and 3.0 T: comparison of oxygenation-sensitive magnetic resonance imaging. Magn Reson Med 2001; 45:595-604.
41. Heiland S, Kreibich W, Reith W, et al. Comparison of echo-planar sequences for perfusion-weighted MRI: which is best? Neuroradiology 1998; 40:216-221.
42. Van Osch MJ, Vonken EJ, Wu O, Viergever MA, van der Grond J, Bakker CJ. Model of the human vasculature for studying the influence of contrast injection speed on cerebral perfusion MRI. Magn Reson Med 2003; 50:614-622.
43. Liu G, Sobering G, Duyn J, Moonen CT. A functional MRI technique combining principles of echo-shifting with a train of observations (PRESTO). Magn Reson Med 1993; 30:764-768.
44. Mattay VS, Frank JA, Duyn JH, et al. Three-dimensional "BURST" functional magnetic resonance imaging: initial clinical applications. Acad Radiol 1996; 3(suppl 2):S379-S383.
45. van Gelderen P, Grandin C, Petrella JR, Moonen CT. Rapid three-dimensional MR imaging method for tracking a bolus of contrast agent through the brain. Radiology 2000; 216:603-608.
46. Grandin CB. Assessment of brain perfusion with MRI: methodology and application to acute stroke. Neuroradiology 2003; 45:755-766.
47. Duyn JH, van Gelderen P, Barker P, Frank JA, Mattay VS, Moonen CT. 3D bolus tracking with frequency-shifted BURST MRI. J Comput Assist Tomogr 1994; 18:680-687.
48. Van Osch MJ, Vonken EJ, Bakker CJ, Viergever MA. Correcting partial volume artifacts of the arterial input function in quantitative cerebral perfusion MRI. Magn Reson Med 2001; 45:477-485.
49. Heiland S, Hartmann M, Sartor K. Is perfusion MRI feasible in lesions with disrupted blood-brain barrier? pitfalls and possible solutions. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2000; 172:812-816. [German]
50. Fiehler J, Knudsen K, Kucinski T, et al. Predictors of apparent diffusion coefficient normalization in stroke patients. Stroke 2004; 35:514-519.
51. Hillis AE, Wityk RJ, Beauchamp NJ, Ulatowski JA, Jacobs MA, Barker PB. Perfusion-weighted MRI as a marker of response to treatment in acute and subacute stroke. Neuroradiology 2004; 46:31-39.
52. Wuerfel J, Bellmann-Strobl J, Brunecker P, et al. Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain 2004; 127:111-119.
53. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Hilaire L, Woolfolk CE. Repeat cerebral blood volume assessment with first-pass MR imaging. J Magn Reson Imaging 1994; 4:457-461.